Risk of ovarian cancer and inherited variants in relapse-associated genes

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Peedicayil, Abraham ^a   Vierkant, Robert A ^a   Hartmann, Lynn C ^a   Fridley, Brooke L ^a   Fredericksen, Zachary S ^a   White, Kristin L ^a   Elliott, Elaine A ^a   Phelan, Catherine M ^b   Tsai, Ya Yu ^b   Berchuck, Andrew ^c   Iversen Jr , Edwin S ^c   Couch, Fergus J ^a   Peethamabaran, Prema ^a   Larson, Melissa C ^a   Kalli, Kimberly R ^a   Kosel, Matthew L ^a   Shridhar, Vijayalakshmi ^a   Rider, David N ^a   Liebow, Mark ^a   Cunningham, Julie M ^a   Schildkraut, Joellen M ^c   Sellers, Thomas A ^b   Goode, Ellen L ^a   more..

^a Mayo Clinic   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H4; MARKER; MESSENGER RNA PRECURSOR;

ARTICLE; CANCER GENETICS; CANCER INVASION; CANCER RELAPSE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; OVARY TUMOR; RECURRENT DISEASE;

AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE;

EID: 77952517603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008884     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108.
2. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11(6): 2149-2155.
3. De Smet F, Pochet NL, De Moor BL, Van Gorp T, Timmerman D, et al. (2005) Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles. Clin Cancer Res 11(21): 7958-7959; author reply 7959.
4. Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, et al. (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28(12): 1207-1215.
5. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, et al. (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Molecular oncology 3(2): 97-137.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer- analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2): 78-85.
7. Pharoah PD, Ponder BA (2002) The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16(4): 449-468.
8. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, et al. (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41(9): 996-1000.
9. Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, et al. (2009) Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 69(6): 2349-2357.
10. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, et al. (2007) Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 67(7): 3027-3035.
11. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, et al. (2008) Consortium analysis of 7 candidate SNPs for ovarian cancer. Intl J Cancer 123(2): 380-388.
12. Zumbrunn J, Trueb B (1996) Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 398(2-3): 187-192.
13. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, et al. (2006) Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116(7): 1994-2004.
14. Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13): 3812-3814.
15. Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, et al. (2008) Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer 98(2): 282-288.
16. Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, et al. (2009) The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res 19(6): 987-993.
17. Smith ER, Cayrou C, Huang R, Lane WS, Cote J, et al. (2005) A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 25(21): 9175-9188.
18. Cooper GM, Hausman RE (2007) The Cell: A Molecular Approach. Sunderlander: Sinauer Associates, Inc.
19. Kelley RL, Solovyeva I, Lyman LM, Richman R, Solovyev V, et al. (1995) Expression of msl-2 causes assembly of dosage compensation regulators on the X chromosomes and female lethality in Drosophila. Cell 81(6): 867-877.
20. Morales V, Straub T, Neumann MF, Mengus G, Akhtar A, et al. (2004) Functional integration of the histone acetyltransferase MOF into the dosage compensation complex. Embo J 23(11): 2258-2268.
21. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4): 391-400.
22. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, et al. (2005) Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1): 2536-2543.
23. Kelemen LE, Sellers TA, Schildkraut JM, Cunningham JM, Vierkant RA, et al. (2008) Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 68(7): 2498-2506.
24. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, et al. (2008) Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(2): 397-404.
25. Cunningham JM, Sellers TA, Schildkraut JM, Fredericksen ZS, Vierkant RA, et al. (2008) Performance of amplified DNA in an Illumina GoldenGate BeadArray assay. Cancer Epidemiol Biomarkers Prev 17(7): 1781-1789.
26. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74(1): 106-120.
27. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164): 851-861.
28. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, et al. (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307(5712): 1072-1079.
29. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS (2002) BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques Suppl: 56-58, 60-51.
30. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2): 263-265.
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8): 904-909.
32. Li Y, Ding J, Abecasis GR (2006) Mach 1.0: Rapid Haplotype Reconstruction and Missing Genotype Inference. Am J Hum Genet s79: 416.
33. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70(2): 425-434.